Second wind for cardiovascular diagnostics: Lantheus revives IPO

Lantheus Holdings, which sells medical imaging agents used in the diagnosis of cardiovascular diseases, revived plans for an upcoming IPO on Friday with blank terms and updated financials for the six months ended June 30, 2014. Lantheus kept the same underwriters as before.

In July, the North Billerica, MA-based company planned to raise $125 million by offering 9.3 million shares at a price range of $12 to $15. However, it postponed the offering.

Private equity firm Avista Capital Partners acquired Lantheus in 2008. Another Avista-backed deal, INC Research (INCR), priced its IPO at the midpoint last night and gained 11% today.

Lantheus Holdings, which traces its roots to 1956 and booked $291 million in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol LNTH. Citi and Jefferies remain the joint bookrunners on the deal.